ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer

Marcus Moses; Alex Niu; Michael B. Lilly; Andrew W Hahn; Roberto Nussenzveig; Elisa Ledet; Charlotte Manogue; Patrick Cotogno; Brian Lewis; Jodi Layton; Neeraj Agarwal; Oliver Sartor; Pedro C. Baratanew
Cancer Treatment and Research Communications2020-7-14DOI: 10.1016/j.ctarc.2020.100193
2阅读
引用收藏
分享

摘要

Background<br/>: The crossover from abiraterone acetate (AA) to enzalutamide (ENZA) is a frequent approach in clinical practice. Our aim was to explore the role of genomic alterations as putative biomarkers of response to sequential AA followed by ENZA in mCRPC and their association with clinical outcomes.<br/>Patients and Methods<br/>: This was a multi-center, retrospective analysis of mCRPC patients with circulating-tumor DNA (ctDNA) post-AA and prior to ENZA treatment. Objectives of this analysis were to assess PSA response, time to PSA progression (TTP) and overall survival (OS) in mCRPC patients treated with ENZA following progression on AA with respect to genomic aberrations detected by ctDNA.<br/>Results<br/>: A total of 28 patients with mCRPC were identified. Median time between AA and ENZA was 3.1 months and median initial PSA prior to ENZA was 35.0 ng/mL. Nine patients (32.1%) achieved PSA responses to ENZA. Most patients (79.0%) achieved confirmed PSA progression with median TTP of 1.6 months (95% CI, 0.7-2.4). Somatic alterations in AR genes were detected in 36.0% of patients with other common alterations detected including 39.0% TP53, 11.0% DNA repair, and 11.0% PTEN. A lack of AR alterations was associated with better PSA response to ENZA (p=0.04).<br/>Conclusion<br/>: While lack of AR alterations in ctDNA was associated with more favorable outcomes, the present dataset is insufficient to recommend the use of ctDNA to impact clinical decision-making in this setting. Further understanding of the implications of the genomic phenotype in ctDNA of castration-resistant tumors and the potential therapeutic implications is required.

学科与关键词

关键词
Abiraterone acetateEnzalutamideCirculating-tumor DNAAndrogen receptorMetastatic castration-resistant prostate cancer
相关
加载中…
  • Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
    Manish Kohli; Winston Tan; Tiantian Zheng; Amy Wang; Carlos Montesinos; Calven Wong; Pan Du; Shidong Jia; Siddhartha Yadav; Lisa G. Horvath; Kate L. Mahon; Edmond M. Kwan; Heidi Fettke; Jianjun Yu; Arun A. AzadEBioMedicine, 2020, 54: 102728.
  • Circulating tumor DNA in patients with metastatic prostate cancer treated with abiraterone acetate
    Loriot, Y.*; Fizazi, K.Annals of Oncology, 2021, 32(6): 694-695.
  • Utility of plasma cell‐free DNA in metastatic castration‐resistant prostate cancer
    Itsuto Hamano; Shingo Hatakeyama; Tomoko Hamaya; Kyo Togashi; Teppei Okamoto; Hayato Yamamoto; Tohru Yoneyama; Takahiro Yoneyama; Yasuhiro Hashimoto; Chikara OhyamaIJU Case Reports, 2020, 3(4): 141-144.
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Treatment and Research Communications
发表日期
2020-07-14
页码
100193
DOI
10.1016/j.ctarc.2020.100193
成果收录
SCIENCEDIRECT

作者

  • M

    Marcus Moses (第一作者)

  • A

    Alex Niu

查看全部 13 位作者收起作者
  • M

    Michael B. Lilly

  • A

    Andrew W Hahn

  • R

    Roberto Nussenzveig

  • E

    Elisa Ledet

  • C

    Charlotte Manogue

  • P

    Patrick Cotogno

  • B

    Brian Lewis

  • J

    Jodi Layton

  • N

    Neeraj Agarwal

  • O

    Oliver Sartor

  • P

    Pedro C. Barata

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417